Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC

(2020) Joe Yeong et al.   JOURNAL OF CLINICAL PATHOLOGY

Peripheral T cell expansion predicts tumour infiltration and clinical response

(2020) Thomas D. Wu et al.   NATURE

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma

(2020) Benjamin P. Fairfax et al.   NATURE MEDICINE

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

(2020) Carlos Hernandez et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

(2020) G. Mazzaschi et al.   LUNG CANCER

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer

(2019) Edwin A. Basak et al.   EUROPEAN JOURNAL OF CANCER

An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade

(2019) Lynda Vuong et al.   CANCER RESEARCH

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

(2019) Tuba N. Gide et al.   CANCER CELL

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance—Letter

(2019) Sander Bins et al.   CLINICAL CANCER RESEARCH

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs

(2019) Carlo Capalbo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

(2019) Steve Lu et al.   JAMA Oncology

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

(2019) Daan P. Hurkmans et al.   Journal for ImmunoTherapy of Cancer

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

(2019) Naga Chalasani et al.   GASTROENTEROLOGY

Cachectic Cancer Patients: Immune to Check-point Inhibitor Therapy?

(2018) Christopher C Coss et al.   CLINICAL CANCER RESEARCH

Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance

(2018) David Turner et al.   CLINICAL CANCER RESEARCH

Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment

(2018) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

(2018) Janet Retseck et al.   Journal of Translational Medicine

Recent advances in mass spectrometry-based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies

(2018) Noriko Iwamoto et al.   PHARMACOLOGY & THERAPEUTICS

The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment

(2018) Mohammad Farhad et al.   OncoImmunology

Evaluation of explant responses to STING ligands: personalized immunosurgical therapy for head and neck squamous cell carcinoma

(2018) Jason R. Baird et al.   CANCER RESEARCH

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Trends in the global immuno-oncology landscape

(2018) Jun Tang et al.   NATURE REVIEWS DRUG DISCOVERY

A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis

(2017) Simon Ritchie et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Salmon provides fast and bias-aware quantification of transcript expression

(2017) Rob Patro et al.   NATURE METHODS

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

(2016) S. A. Harrison et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

Interferon-  Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade

(2016) M. J. McNamara et al.   Cancer Immunology Research

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of Alternative Macrophage Activation by Galectin-3

(2014) A. C. MacKinnon et al.   JOURNAL OF IMMUNOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis

(2013) Noriko Iwamoto et al.   ANALYST

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees

(2013) Joyce N. Barlin et al.   GYNECOLOGIC ONCOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors

(2013) Peter G. Traber et al.   PLoS One

Abstract 5757: A new functional classification of lung and breast cancers based on siRNA mediated knockdown of 48 NRs and 72 CoRegulators

(2012) Ryan Carstens et al.   CANCER RESEARCH

Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response

(2012) K. Franciszkiewicz et al.   CANCER RESEARCH

Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression

(2012) Yuan-Guo Wang et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model

(2012) P. Yu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages

(2011) Ruder Novak et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice

(2010) N. Demotte et al.   CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Galectin-3 regulates T-cell functions

(2009) Daniel K. Hsu et al.   IMMUNOLOGICAL REVIEWS

Expression Profiling of Galectin-3-Depleted Melanoma Cells Reveals its Major Role in Melanoma Cell Plasticity and Vasculogenic Mimicry

(2008) Alexandra A. Mourad-Zeidan et al.   AMERICAN JOURNAL OF PATHOLOGY

Galectins: structure, function and therapeutic potential

(2008) Ri-Yao Yang et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE